Last reviewed · How we verify
ENN0403, high dose
ENN0403 is a high-dose investigational drug with an unknown mechanism of action.
At a glance
| Generic name | ENN0403, high dose |
|---|---|
| Sponsor | EnnovaBio |
| Modality | Small molecule |
| Phase | Phase 2 |
Mechanism of action
Due to limited information, the exact mechanism of action for ENN0403 is not well understood.
Approved indications
Common side effects
Key clinical trials
- A Phase 2 Study to Evaluate the Efficacy and Safety of ENN0403 in Subjects with DME (PHASE2)
- Efficacy and Safety of ENN0403 in Patients At High Risk for Acute Kidney Injury Following Elective Cardiac Surgery (PHASE2)
- A First-in-human Single Ascending Dose/Multiple Ascending Dose Study of ENN0403 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ENN0403, high dose CI brief — competitive landscape report
- ENN0403, high dose updates RSS · CI watch RSS
- EnnovaBio portfolio CI